VOTRIENT 200 MG
PAZOPANIB (PAZOPANIB HYDROCHLORIDE) : 200 MG · DIN 02352303 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is VOTRIENT?
VOTRIENT 200 MG contains PAZOPANIB (PAZOPANIB HYDROCHLORIDE) : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02352303, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Sep-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VOTRIENT used for?
VOTRIENT (pazopanib hydrochloride) is indicated for the treatment of patients with metastatic renal cell (clear cell) carcinoma (mRCC) as first-line systemic therapy or as second-line systemic therapy after treatment with cytokines for metastatic disease. VOTRIENT (pazopanib hydrochloride) is also indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02352303 |
|---|---|
| Brand name | VOTRIENT |
| Generic / active ingredient | PAZOPANIB (PAZOPANIB HYDROCHLORIDE) : 200 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EX03 PAZOPANIB |
| AHFS class | 28:36.20.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Sep-2016 |
| Original market date | 2010-06-16 00:00:00 |
How is it stored and handled?
null
How is it supplied?
bottles of 120 tablets
What can be used instead?
Other Canadian products sharing ATC code L01EX03 PAZOPANIB. 3 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EUGIA-PAZOPANIB | 200 MG | TABLET | EUGIA PHARMA INC. | MARKETED | DIN 02552957 |
| PMS-PAZOPANIB | 200 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02525666 |
| SANDOZ PAZOPANIB | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02521180 |
| VOTRIENT | 400 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED PRE MARKET | DIN 02352311 |
Who else supplies PAZOPANIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PAZOPANIB appears in 292 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.